Illumina has reported 16.3% average annual revenue growth over the past 4 quarters, increasing from $961.0M in Q4 2024 to $1.2B in the most recent Q3 2025. The company's net margin has expanded from 16.1% in Q4 2024 to 19.1% in Q3 2025, driven by improved operating leverage and pricing power. Illumina has also generated robust free cash flow, with $256.0M in Q3 2025 representing 21.3% of revenue. The company's disciplined capital allocation, including strategic investments and share repurchases, has strengthened its balance sheet. Illumina's dominant market position, commitment to innovation, and financial discipline position the company well to capitalize on the ongoing growth in genetic sequencing and personalized medicine. The company's ability to steadily expand margins while delivering double-digit revenue growth is a testament to the strength of its business model. Given Illumina's momentum, I expect the company to maintain its growth trajectory, with revenue reaching $5.2B and EPS of $7.80 by the end of 2027, representing a 15% and 20% CAGR respectively from the current 4Q data. This outlook is supported by the company's robust product pipeline, strategic partnerships, and market leadership.

Research these companies